01:51 PM EDT, 05/30/2025 (MT Newswires) -- Labcorp ( LH ) said Friday it is expanding its precision oncology portfolio with the addition of new tests for solid tumors and hematologic malignancies.

The company announced the availability of new NGS panels for myeloid, lymphoid and pan-heme indications, providing broader genomic coverage and "more clinically actionable" insights for patients who have hematologic malignancies.

Labcorp ( LH ) also launched a panel that improves the company's test menu for acute myeloid leukemia.

The company also announced improved biopharma services that support accelerated clinical studies and companion diagnostic development.

Price: 248.01, Change: +1.26, Percent Change: +0.51